---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086740"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:49:25.580415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway

## Summary
- Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.
- Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.
- FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.
- Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.
- Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter.

## SEC filing metadata
- accession: 0001104659-24-086740
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/0001104659-24-086740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/tm2421059d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086740
- JSON: https://secwatch.observer/filing/0001104659-24-086740.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.